Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on December 12, 2023, before market open. The Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data, featuring Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.
12/11/2023 - 04:05 PM
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data. The call will feature a discussion with Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.
Conference Call and Webcast Presentation Click Here
A replay of the webcast and accompanying presentation will be available following the event on the Presentations, Events & News page of the Investors section of the Connect Biopharma website.
About Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is an investigational antagonist of histamine receptor 3 designed to act peripherally, in development for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/
Investor Contact
Tim McCarthytim@lifesciadvisors.com
Media Contact
Mari Purpurampurpura@lifesciadvisors.com
What is the date of the presentation of top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma by Connect Biopharma Holdings Limited (Nasdaq: CNTB)?
The presentation will take place on December 12, 2023, before market open.
Who will be discussing the top-line data during the conference call and webcast presentation by Connect Biopharma Holdings Limited (Nasdaq: CNTB)?
Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting, will be leading the discussion.
Where can I find the replay of the webcast and accompanying presentation by Connect Biopharma Holdings Limited (Nasdaq: CNTB)?
The replay will be available on the Presentations, Events & News page of the Investors section of the Connect Biopharma website.
